Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) shares traded -23.75% lower at $0.31 on Wall Street last session.
In accordance with the data, 1 analysts cover Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $10.00, we find $10.00. Given the previous closing price of $0.40, this indicates a potential upside of 2400.0 percent. BCLI stock price is now 44.82% away from the 50-day moving average and -81.81% away from the 200-day moving average. The market capitalization of the company currently stands at $14.94M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
It has been rated a hold by 1 analysts and a buy by 0. Brokers who have rated the stock have averaged $10.00 as their price target over the next twelve months.
With the price target maintained at $12, Maxim Group recently Upgraded its rating from Hold to Buy for Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI).
In other news, Lindborg Stacy, Co-Chief Executive Officer bought 11,500 shares of the company’s stock on Sep 01. The stock was bought for $20,402 at an average price of $1.77. Upon completion of the transaction, the Co-Chief Executive Officer now directly owns 181,500 shares in the company, valued at $56265.0. A total of 19.17% of the company’s stock is owned by insiders.
Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) opened at $0.4400 on Tuesday. During the past 12 months, Brainstorm Cell Therapeutics, Inc. has had a low of $0.13 and a high of $3.46. The fifty day moving average price for BCLI is $0.2020 and a two-hundred day moving average price translates $1.6681 for the stock.
The latest earnings results from Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) was released for Sep, 2023.
Brainstorm Cell Therapeutics, Inc.(BCLI) Company Profile
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer’s disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
